司库奇尤单抗可能是合并中枢神经系统脱髓鞘疾病和强直性脊柱炎患者的有效治疗选择：两例临床病例报告。
Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases.
机构信息
Department of Human Neurosciences, Sapienza University of Rome, v.le dell'Università 30, 00185 Rome, Italy.
Department of Internal Medicine and Medical Specialties, Rheumatology, Sapienza University of Rome, p.le Aldo Moro 5, 00185 Rome, Italy.
出版信息
Mult Scler Relat Disord. 2019 Oct;35:193-195. doi: 10.1016/j.msard.2019.08.006. Epub 2019 Aug 5.
The therapeutic approach to CNS demyelination associated to ankylosing spondylitis is a complex issue due to the contraindication of TNF inhibitors in demyelinating diseases. Secukinumab, a human IgG1κ monoclonal antibody that binds and inhibits IL-17A, was recently approved for the treatment of ankylosing spondylitis. We report the clinical cases of two patients affected by a CNS demyelinating disease and ankylosing spondylitis who were successfully treated with secukinumab, providing additional evidence of the feasibility of this therapeutic option when the use of TNF inhibitors is discouraged by challenging comorbidities.
由于 TNF 抑制剂在脱髓鞘疾病中的禁忌，与强直性脊柱炎相关的中枢神经系统脱髓鞘的治疗方法是一个复杂的问题。司库珠单抗，一种人源 IgG1κ 单克隆抗体，可结合并抑制 IL-17A，最近被批准用于治疗强直性脊柱炎。我们报告了两名患有中枢神经系统脱髓鞘疾病和强直性脊柱炎的患者的临床病例，他们成功地接受了司库珠单抗治疗，这为在存在具有挑战性的合并症而不鼓励使用 TNF 抑制剂时，这种治疗选择的可行性提供了额外的证据。
Zotero 插件